AML3D LIMITED — Capital/Financing Update 2020

Dec 6, 2020

ASX Release 07 December 2020

==> picture [76 x 68] intentionally omitted <==

ASX CODE: AL3

CAPITAL STRUCTURE

Share Price $0.43 Shares on Issue 149m Market Capitalisation $64m (as at 07/12/20)

NEXT-GEN BODY ARMOUR PROGRAM PROGRESSES TO STAGE 2

MAJOR SHAREHOLDERS

HIGHLIGHTS

Andrew Sales 26.5% Perennial Value Mgmt 9.0%

BOARD & MANAGEMENT

Stephen Gerlach AM Non-Executive Chairman

Andrew Sales Managing Director

• AML3D enters Stage 2 with Lightforce in the development of nextgeneration, ‘made-to-fit’ titanium body armour

• Under Stage 2, AML3D will develop additional prototypes to undertake repeatability ballistics testing

• Lightforce is a developer and manufacturer of defence solutions with operations in Australia and the United States

• Body armour market is expected to exceed US$3.0bn by 2025[1]

Sean Ebert Executive Director

Kevin Reid Non-Executive Director

Len Piro Non-Executive Director

Christine Manuel Company Secretary

CONTACT

T: +61 8 8258 2658 E: investor@aml3d.com

W: www.aml3d.com

A: 35 Woomera Ave Edinburgh SA 5111

P: PO BOX 4101 Tranmere SA 5073

ABN: 55 602 857 983

AML3D Limited (ASX:AL3) (‘ AML3D ’ or ‘ the Company ’) is pleased to announce it has progressed to Stage 2 in the development of next-generation, ‘made-to-fit’ titanium body armour with Lightforce Australia Pty Ltd (‘ Lightforce ’).

AML3D’s Wire Arc Manufacturing (‘ WAM® ’) possesses a unique capability to efficiently print bespoke body armour, a function not possible using traditional subtractive techniques (forging, casting). This capability may facilitate the development of a new product range, whereby the torso of a soldier is scanned to manufacture a ‘made-to-fit’ solution. This innovative, world-first offering will be a true disruptor in an industry that is expected to exceed US$3.0bn by 2025 (CAGR of 5.5%).[1]

Progression to Stage 2 follows excellent results from Stage 1 product testing[2] and enhances the significance of the Memorandum of Understanding (“ MoU ”) and the pathway to commercialisation.

Under Stage 2, AML3D will develop additional prototypes to undertake repeatability ballistics testing. The prototypes will be of varying thicknesses and finished with a range of techniques and/or treatments to further enhance ballistic performance. These tests will enable AML3D to optimise the design in an effort to deliver the lightest and strongest solution on the market.

The purchase order to produce the Stage 2 prototypes to provide to Lightforce for testing is valued at $50k+GST, on usual commercial purchase order terms including 30 day payment.

1. https://www.grandviewresearch.com/press-release/global-body-armor-market 2. Excellent results from next-gen body armour testing for Lightforce – 29 July 2020

ASX Release 07 December 2020

==> picture [63 x 48] intentionally omitted <==

Finalisation of Stage 2 will signify the end of the testing phase under the MoU. Given the results to date, AML3D is confident that these subsequent tests will be successful, leading to the initiation of commercial discussions.

In the event of commercialisation, the scale of opportunity combined with Lightforce’s established customer base has the potential to result in significant contract manufacturing revenues.

Mr Andrew Sales, AML3D’s Managing Director comments:

“We’re excited to progress to Stage 2 with Lightforce in the development of a disruptive, worldfirst product offering. We’re confident that our highly qualified team will be able to deliver a range of prototypes that meet or exceed Lightforce’s required specifications.” Mr Sales added, “Post the recent capital raise, AML3D is now well capitalised to fulfil the demands of opportunities such as Lightforce, which have the potential to deliver significant contract manufacturing revenues.”

This announcement has been authorised for release by the Board of AML3D.

For further information, please contact:

Andrew Sales Duncan Gordon Managing Director Executive Director AML3D Limited Adelaide Equity Partners T: +61 8 8258 2658 T: +61 404 006 444 E: investor@aml3d.com E: dgordon@adelaideequity.com.au

About AML3D Limited

AML3D(ASX:AL3) is an Australian public company redefining the standards of productivity. Incorporated in 2014, AML3D utilises 3D printing to solve complex challenges with metallurgy, patented WAM® process, proprietary software WAMSoft®, creating certified, industrial products more sustainably. AML3D provides additive manufacturing on demand services in contract manufacturing centres and is the original equipment manufacturer of Arcemy®, metal 3D printers that utilise local materials to manufacture high performance products closer to the location of use.

AML3D Limited (ASX:AL3)

Page | 2